VITAMIN D3 INHIBITS GROWTH OF HODGKIN CELL LINES AND IMPROVES SENSITIVITY TO CHEMOTHERAPY AT PHYSIOLOGICAL DOSES IN VITRO AND IN VIVO.

EHA Library, Melita Cirillo, 266934

LONG TERM FOLLOW-UP OF WALDENSTRÖM MACROGLOBULINEMIA PATIENTS PRIMARY TREATED WITH DEXAMETHASONE, RITUXIMAB, AND CYCLOPHOSPHAMIDE : A SINGLE CENTRE EXPERIENCE

EHA Library, vittorio del fabro, 266935

MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19+ SELECTED AND UNSELECTED SAMPLES

EHA Library, Daniela Drandi, 266936

CDCA7 REGULATES LYMPHOMA CELLS MIGRATION, INVASIVENESS AND THEIR MICROTUBULE AND ACTOMYOSIN CYTOSKELETONS DYNAMICS.

EHA Library, Carla Martín-Cortázar, 266937

INHIBITION OF NOTCH SIGNALING RESTORES SENSITIVITY TO IMMUNOCHEMOTHERAPY IN AN IN VITRO MODEL OF ACQUIRED RESISTANCE TO R-CHOP

EHA Library, Giovanni Di Pinto, 266938

ASTX660, A NON-PEPTIDOMIMETIC ANTAGONIST OF CIAP1/2 AND XIAP, INDUCES APOPTOSIS IN T CELL LYMPHOMA BY ENHANCING IMMUNE MEDIATED AND DEATH RECEPTOR DEPENDENT KILLING.

EHA Library, Martin Sims, 266939

HIGH SERUM LEVELS OF IL-2R, IL-6 AND TNF ARE ASSOCIATED WITH HIGHER TUMOR BURDEN AND POORER OUTCOME IN PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA

EHA Library, Pablo Mozas, 266940

GENETIC SIMILARITY BETWEEN WALDENSTRÖM MACROGLOBULINEMIA AND IGG-TYPE LYMPHOPLASMACYTIC LYMPHOMA. TARGETED NEXT-GENERATION SEQUENCING RESULTS OF FORMALIN-FIXED PARAFFIN EMBEDDED SAMPLES

EHA Library, Maaya Awata, 266941

IDENTIFICATION AND TARGETING OF MOLECULAR SIGNATURES OF HYPOMETHYLATING AGENT RESISTANCE IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA

EHA Library, Yue Wei, 266942

IMPLEMENTATION OF FUNCTIONAL ASSAYS TO CHARACTERIZE AND DETERMINE THE CLINICAL IMPACT OF RUNX1 VARIANTS OF UNCERTAIN SIGNIFICANCE IN SPORADIC DISEASES AS WELL AS IN THE CONTEXT OF FPDMM

EHA Library, Tim Ripperger, 266943

PRO-NECROPTOTIC RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BONE MARROW OF PATIENTS WITH MDS AND CMML

EHA Library, Veronika Dill, 266944

ABNORMAL LEVELS OF FUNCTIONAL CTLS ON HIGH RISK MDS PATIENTS UNDER AZACYTIDINE TREATMENT

EHA Library, Zoi Bezirgiannidou, 266945

IN VIVO 18F-FLUORO-THYMIDINE POSITRON EMISSION TOMOGRAPHY IMAGING FOR DISEASE MONITORING IN A MOUSE MODEL OF HIGH-RISK MYELODYSPLASTIC SYNDROME

EHA Library, Rose-Ann Padua, 266946

VARIABILITY IN THE EXTENT OF DEL(5Q) AND ITS CLINICAL IMPLICATION IN MYELODYSPLASTIC SYNDROMES (MDS).

EHA Library, Zuzana Zemanova, 266947

MYELOMONOCYTIC SKEWING IN CHRONIC MYELOMONOCYTIC LEUKEMIA: PHENOTYPIC, GENOTYPIC AND BIOLOGIC FEATURES AND IMPACT ON SURVIVAL

EHA Library, Klaus Geissler, 266948

RIGOSERTIB MODULATES HEMATOPOIESIS GENE SIGNALING PATHWAYS ALONE OR IN SEQUENCED COMBINATION WITH AZACTIDINE ON MDS CELLS IN VITRO.

EHA Library, Lewis Silverman, 266949

OVEREXPRESSION OF PROTEIN TYROSINE PHOSPHATASE NON-RECEPTOR TYPE1 CAUSES STAT5 DEPHOSPHORYLATION, RESULTING IN SUPPRESSION OF CELL GROWTH SIGNAL IN K562 HUMAN LEUKEMIA CELLS

EHA Library, Masayuki SHISEKI, 266950

THERAPEUTIC RESPONSE OF MYELODYSPLASTIC SYNDROMES TO EPIGENETIC DRUGS INDEPENDENTLY OF ENDOGENOUS RETROELEMENT MODULATION

EHA Library, Zoi Bezirgiannidou, 266951

ANALYSIS OF REACTIVE OXYGEN SPECIES IN MDS HEMATOPOIETIC STEM AND PROGENITOR CELLS AND THEIR CORRELATIONS WITH CLINICAL DATA.

EHA Library, Valentina Giai, 266952

DISCREPANCE OF ALLELIC BURDEN CHANGES AND CLINICAL RESPONSE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS

EHA Library, Joon Ho MOON, 266953

IVOSIDENIB (AG-120) INDUCES DURABLE REMISSIONS AND TRANSFUSION INDEPENDENCE IN PATIENTS WITH IDH1-MUTANT RELAPSED/REFRACTORY MYELODYSPLASTIC SYNDROME IN A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY

EHA Library, James M. Foran, 266954

TEMPORAL TRENDS IN TRANSFUSION BURDEN AMONG NEWLY DIAGNOSED PATIENTS WITH MYELODYSPLASTIC SYNDROMES: A U.S. CLAIMS DATABASE STUDY

EHA Library, S. Lane Slabaugh, 266955

UNSUPERVISED HIERARCHICAL CLUSTERING OF PRE-TREATMENT IMMUNOPHENOTYPIC FEATURES IDENTIFIES MDS PATIENTS AT HIGH RISK OF DISEASE PROGRESSION AFTER ALLOGENEIC TRANSPLANTATION

EHA Library, Madlen Jentzsch, 266956

ABSOLUTE MONOCYTE COUNT AFFECTS PROGNOSIS IN MYELODYSPLASTIC SYNDROMES INDEPENDENTLY FROM THE IPSS-R

EHA Library, Tobias Silzle, 266957

CLINICAL SIGNIFICANCE OF KIR GENOTYPE IN JAPANESE PATIENTS WITH MYELODYSPLASTIC SYNDROME

EHA Library, Norina Tanaka, 266958

PREDICTING SURVIVAL AND TRANSFORMATION IN YOUNG AND MIDDLE-AGED PATIENTS WITH MYELODYSPLASTIC SYNDROME

EHA Library, Natallia Klimkovich, 266959

ARE MYELODYSPLASTIC SYNDROMES WITH ISOLATED 20Q DELETION A DIFFERENT CLINICAL-BIOLOGICAL ENTITY?

EHA Library, Alessia Campagna, 266960

PHASE 1/2 STUDY OF DSP-7888 IN PATIENTS WITH HIGHER-RISK (HR) MYELODYSPLASTIC SYNDROMES (MDS) AFTER FAILURE OF AZACITIDINE (AZA) THERAPY

EHA Library, Kensuke Usuki, 266961

CIRCULATING TUMOR DNA AS A LIQUID BIOPSY IN SMOLDERING MULTIPLE MYELOMA TO IDENTIFY BIOMARKERS OF PROGRESSION

EHA Library, Martina Manzoni, 266962

CLONAL EVOLUTION IN MULTIPLE MYELOMA PATIENTS RECEIVING MAINTENANCE THERAPY

EHA Library, Carolina Terragna, 266963

PHF19 INDUCES EZH2 PHOSPHORYLATION AND PROMOTES DRUG RESISTANCE IN MULTIPLE MYELOMA

EHA Library, Chen-Xing Du, 266964

DETAILED PHENOTYPIC, MOLECULAR AND FUNCTIONAL PROFILING OF MYELOID DERIVED SUPPRESSOR CELLS (MDSCS) IN THE TUMOR IMMUNE MICRO-ENVIRONMENT (TIME) OF MULTIPLE MYELOMA (MM)

EHA Library, Cristina Pérez Ruiz, 266965

UPDATED RISK STRATIFICATION MODEL FOR SMOLDERING MULTIPLE MYELOMA (SMM) INCORPORATING THE REVISED IMWG DIAGNOSTIC CRITERIA

EHA Library, María-Victoria Mateos, 266966

STRONG PRE-CLINICAL RATIONAL FOR THE USE OF MCL1/BCL2 BH3 MIMETIC COMBINATION TO EFFECTIVELY KILL PRIMARY MYELOMA CELLS INSENSITIVE TO EACH BH3 MIMETIC ALONE

EHA Library, Carolane Seiller, 266967

CRITICAL ANALYSIS OF THE STRINGENT COMPLETE RESPONSE IN MULTIPLE MYELOMA. AN UPDATED OF THE ANALYSIS BASED ON THE PETHEMA/GEM2012MENOS65 PHASE III CLINICAL TRIAL.

EHA Library, Joaquín Martinez-Lopez, 266968

DISSECTING THE BONE MARROW IMMUNE MICROENVIRONMENT IN THE COMPLETE SPECTRUM OF MONOCLONAL GAMMOPATHIES: POTENTIAL IMPLICATIONS IN DISEASE PATHOGENESIS

EHA Library, Noemi Puig, 266969

PROGNOSTIC IMPACT OF T(8Q24)/CMYC IN MULTIPLE MYELOMA

EHA Library, Tatiana Abramova, 266970

MYELOMA-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION

EHA Library, Saeko Ota, 266971

FITNESS SIGNATURES IN MULTIPLE MYELOMA PROGRESSION AND RESISTANCE

EHA Library, Santiago Barrio, 266974

POTENT ANTI-MYELOMA EFFICACY OF DENDRITIC CELL THERAPY IN COMBINATION WITH POMALIDOMIDE AND PROGRAMMED DEATH-LIGAND 1 BLOCKADE IN A PRECLINICAL MODEL OF MULTIPLE MYELOMA

EHA Library, Je-Jung Lee, 266975

DYSREGULATED MICRORNA EXPRESSION IN CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA

EHA Library, Jana Gregorová, 266976

LONG NON-CODING RNA NEAT1 TARGETING TRIGGERS ANTI-TUMOR ACTIVITY AND RESULTS IN CHEMO-SENSITIZING EFFECT IN MULTIPLE MYELOMA CELLS

EHA Library, Elisa Taiana, 266977

BIDIRECTIONAL MITOCHONDRIAL TRANSFER BETWEEN MYELOMA CELLS AND BONE MARROW STROMAL CELLS CONTRIBUTES TO THE CHEMORESISTANCE OF MYELOMA CELLS

EHA Library, Zsolt Matula, 266978

TRYPTOPHAN DEPRIVATION DUE TO INCREASED IDO-1 TRIGGERS A METABOLIC ADAPTIVE RESPONSE AND DOWN-REGULATES CD38 IN MULTIPLE MYELOMA

EHA Library, Alessandra Romano, 266979

TARGETING MITOCHONDRIAL FITNESS OF MYELOMA CELLS WITH TAK-242 OVERCOMES BORTEZOMIB RESISTANCE

EHA Library, Cesarina Giallongo, 266980

EXOSOMAL CARGO IN MONOCLONAL GAMMOPATHIES COMPARED TO HEALTHY DONORS AND ITS POTENTIAL RELATION TO MYELOMA AGGRESSIVENESS.

EHA Library, Bruna Ferreira, 266981

NEXT-GENERATION OPTICAL MAPPING REVEALS LARGE GENETIC HETEROGENEITY IN MULTIPLE MYELOMA

EHA Library, Anna PETRACKOVA, 266982

TISSUE ENGINEERING OF AN ORTHOTOPIC HUMANIZED BONE-ORGAN AS A PLATFORM FOR PRECLINICAL MULTIPLE MYELOMA RESEARCH

EHA Library, Alvaro Sanchez, 266983

COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN

EHA Library, Takashi Kanamori, 266984

IGH AND IGK REARRANGEMENT AND IGH SOMATIC HYPERMUTATION ANALYSIS USING NEXT-GENERATION SEQUENCING FOR THE DETECTION OF CLONALITY IN HIGH-RISK KOREAN MULTIPLE MYELOMA PATIENTS

EHA Library, Jiwon Lee, 266985

AMITRIPTYLINE STRENGTHENS THE EFFECTS OF BORTEZOMIB AND MELPHALAN TREATMENT IN MULTIPLE MYELOMA BY INHIBITING ACID SPHINGOMYELINASE.

EHA Library, K Maes, 266986

ELOTUZUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: EFFICACY RESULTS AFTER ADDITIONAL FOLLOW-UP OF THE PHASE 2, RANDOMIZED ELOQUENT-3 STUDY

EHA Library, PAUL RICHARDSON, 266987

ELOTUZUMAB IN COMBINATION WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRD) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): A PHASE 2 MMRC TRIAL

EHA Library, Jagoda Jasielec, 266988

B-CELL MATURATION ANTIGEN ANTIBODY-DRUG CONJUGATE (ADC), GSK2857916, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL SAFETY, EFFICACY AND PHARMACOKINETIC (PK) ANALYSES FROM A PHASE I STUDY

EHA Library, Rakesh Popat, 266989

A TWENTY-FOUR YEAR EXPERIENCE OF AUTOLOGOUS STEM CELL TRANSPLANTATION FOR LIGHT CHAIN AMYLOIDOSIS PATIENTS IN THE UNITED KINGDOM

EHA Library, Faye Sharpley, 266990

PROGNOSIS IN ELDERLY MULTIPLE MYELOMA PATIENTS IN THE HOVON-87/NMSG-18 STUDY BASED ON REVISED ISS AND SKY92-ISS

EHA Library, Rowan Kuiper, 266991

UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Luciano J. Costa, 266992

LENALIDOMIDE MAINTENANCE POSITIVELY IMPACTS OUTCOMES IN MULTIPLE MYELOMA WITHOUT NEGATIVE IMPACTS IN RELAPSE: AN ANALYSIS OF REAL WORLD DATA FROM THE MYELOMA CANADA RESEARCH NETWORK NATIONAL DATABASE

EHA Library, Christopher Venner, 266993

IMPROVEMENT IN HEALTH-RELATED QUALITY OF LIFE FOR NEWLY DIAGNOSED MULTIPLE MYELOMA TRANSPLANT-ELIGIBLE PATIENTS TREATED WITH DARATUMUMAB, BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE: CASSIOPEIA STUDY

EHA Library, Murielle Roussel, 266994

AN EARLY, WITHIN THE FIRST MONTH, AND DEEP RESPONSE, SHOULD BE THE GOAL OF THERAPY IN AL AMYLOIDOSIS

EHA Library, Efstathios Kastritis, 266995

SAFETY AND EFFICACY OF ONCE-WEEKLY CARFILZOMIB DOSING IN FRAIL PATIENTS: A SUBGROUP ANALYSIS FROM THE PHASE 3 A.R.R.O.W. STUDY

EHA Library, María-Victoria Mateos, 266996

PEPTIDE VACCINATION AGAINST PD-L1 (IO103) IN MULTIPLE MYELOMA - A PHASE I FIRST IN HUMAN TRIAL

EHA Library, Nicolai Jørgensen, 266997

A PHASE 2 TRIAL OF THE COMBINATION OF IXAZOMIB, THALIDOMIDE AND DEXAMETHASONE (ITD) IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA - THE AMARC 16-02 TRIAL

EHA Library, Andrew Spencer, 266998

DEEPENING RESPONSES SEEN WITH IXAZOMIB MAINTENANCE POST-AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) ARE ASSOCIATED WITH PROLONGED PROGRESSION-FREE SURVIVAL - ANALYSIS FROM THE TOURMALINE-MM3 STUDY

EHA Library, Hartmut Goldschmidt, 266999

A SEQUENTIAL COHORT STUDY COMPARING KAPPAMAB ALONE TO KAPPAMAB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN KAPPA-RESTRICTED RELAPSED REFRACTORY (RR) MULTIPLE MYELOMA (AMARC 01-16)

EHA Library, Anna Kalff, 267000

TREATMENT CHOICES AND OUTCOMES FOR PATIENTS WITH MULTIPLE MYELOMA AFTER RELAPSE ON LENALIDOMIDE MAINTENANCE THERAPY: RESULTS FROM THE CONNECT® MM REGISTRY

EHA Library, Sundar Jagannath, 267001

THE IMPACT OF A PRIOR MALIGNANCY ON THE DEVELOPMENT OF A SUBSEQUENT MALIGNANCY IN MULTIPLE MYELOMA REVISITED: A COMPETING RISK ANALYSES

EHA Library, Mirian Brink, 267002

CARFILZOMIB AS PART OF A DOSE DENSE, LESS DOSE INTENSE TOTAL THERAPY APPROACH FOR HIGH RISK MYELOMA

EHA Library, Frits van Rhee, 267003

CARFILZOMIB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS FROM PHASE 3 ASPIRE AND ENDEAVOR

EHA Library, Thierry Facon, 267004

RELATIVE EFFICACY OF APPROVED AND RECENTLY INTRODUCED TREATMENTS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A NETWORK META-ANALYSIS

EHA Library, Katja Weisel, 267005

IMPACT OF DIFFERENT MAINTENANCE THERAPY OPTIONS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA AT MD ANDERSON CANCER CENTER

EHA Library, Mohammed Shazly, 267006

PRELIMINARY DATA: PHASE 1B STUDY OF FEASIBILITY/SAFETY OF ISATUXIMAB SHORT DURATION FIXED VOLUME INFUSION IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Saad Usmani, 267007

ASSESSMENT OF THE BURDEN OF DISEASE IN TERMS OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MULTIPLE MYELOMA NOT ELIGIBLE FOR ASCT IN SPAIN: INTERIM ANALYSIS OF QOLMMBUS STUDY

EHA Library, Javier DE LA RUBIA, 267008

CONSOLIDATION WITH A SHORT COURSE OF DARATUMUMAB CAN SIGNIFICANTLY IMPROVE COMPLETE RESPONSE RATES IN PATIENTS WITH AL AMYLOIDOSIS OR LCDD

EHA Library, Efstathios Kastritis, 267009

PRIMARY TREATMENT OF LIGHT CHAIN (AL) AMYLOIDOSIS WITH BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD)

EHA Library, Efstathios Kastritis, 267010

FLOW-MEDIATED DILATATION AND AORTIC BLOOD PRESSURE PREDICT CARDIOVASCULAR ADVERSE EVENTS DURING CARFILZOMIB TREATMENT: A PROSPECTIVE STUDY IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA.

EHA Library, Efstathios Kastritis, 267011

COMPARATIVE EFFECTIVENESS OF FRONT-LINE TREATMENTS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO ARE TRANSPLANT INELIGIBLE

EHA Library, Thierry Facon, 267012

RESULTS OF PHASE I/II STUDY OF NIVOLUMAB WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS WITH SUBOPTIMAL RESPONSE TO PRIMARY INDUCTION THERAPY

EHA Library, Olga PIROGOVA, 267013

OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA

EHA Library, Brett Grieb, 267014

RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT

EHA Library, Julio Davila Valls, 267015

REAL WORLD DATA ON THE EFFICACY AND SAFETY OF DARATUMUMAB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS: A MULTI-SITE RETROSPECTIVE STUDY.

EHA Library, Yael C Cohen, 267016

ASSESSMENT OF SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA BY USING MODIFIED RISK STRATIFICATION MSMART 3.0

EHA Library, Sergey Voloshin, 267017

PATIENT REPORTED EXPERIENCE FROM PART 2 OF THE FIRST TIME IN HUMAN STUDY OF THE BCMA ANTIBODY DRUG CONJUGATE GSK2857916 FOR ADVANCED RELAPSED REFRACTORY MULTIPLE MYELOMA (DREAMM-1)

EHA Library, Rakesh Popat, 267018

OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM.

EHA Library, Camila PeA a, 267019

IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) IN EUROPE: A HETEROGENEOUS DISEASE TREATED WITH A VARIETY OF AGENTS

EHA Library, Louis Terriou, 267020

RELATIONSHIP BETWEEN COMORBIDITY AND ELIGIBILITY CRITERIA FOR CLINICAL TRIALS IN MULTIPLE MYELOMA. A CRITICAL APPRAISAL.

EHA Library, Ernesto Pérez Persona, 267021

USE OF POMALIDOMIDE-BASED REGIMENS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN FOUR EUROPEAN COUNTRIES - FINDINGS FROM PREAMBLE

EHA Library, Philippe Moreau, 267022

WEEKLY CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE UNTIL PROGRESSION IN RELAPSED REFRACTORY MULTIPLE MYELOMA

EHA Library, Cécile Gruchet, 267023

TWICE WEEKLY CARFILZOMIB IS AN ACCEPTED TREATMENT BY PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY: INTERIM RESULTS OF THE CARO STUDY

EHA Library, Wolfgang Knauf, 267024

PROGNOSTIC SIGNIFICANCE OF CD56 EXPRESSION ON BONE MARROW PLASMA CELLS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.

EHA Library, Giulia Rivoli, 267025

RESULTS OF THE FREQUENCY AND CAUSES OF DISCONTINUATION OF THE SUCESIVE THERAPEUTIC LINES IN PATIENTS WITH MULTIPLE MYELOMA: REAL LIFE DATA FROM A SINGLE SPANISH CENTER

EHA Library, Ana García Feria, 267026

DARATUMUMAB IS WELL TOLERATED AND INDUCES A RAPID HEMATOLOGICAL RESPONSE IN NON IG-M LIGHT CHAIN AMYLOIDOSIS WITH SEVERE CARDIAC IMPAIRMENT.

EHA Library, Romain Gounot, 267027

CHARACTERISTICS AND TREATMENT OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NON-STEM CELL TRANSPLANT (NSCT) PATIENTS IN THE UK, GERMANY, AND FRANCE

EHA Library, Dorothy Romanus, 267028

POMALIDOMIDE 3RD LINE VERSUS 4TH LINE FOR IN EARLY RELAPSED REFRACTORY MULTIPLE MYELOMA

EHA Library, Cécile Gruchet, 267029

INCIDENCE OF NEGATIVE MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANT

EHA Library, Carolina Afonso, 267030

A PHASE 1B/2 STUDY OF SELINEXOR, CARFILZOMIB, AND DEXAMETHASONE (SKD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Cristina J. Gasparetto, 267031

SURVIVAL OF MULTIPLE MYELOMA PATIENTS DIAGNOSED 1970-2015: REAL-WORLD DATA FROM A SINGLE CENTER

EHA Library, Luis Gerardo Rodríguez-Lobato, 267032

EVOLVING TREATMENT PATTERNS IN NON-STEM CELL TRANSPLANT (NSCT) NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS FROM A REAL-WORLD CHART REVIEW IN FRANCE, GERMANY, AND THE UK

EHA Library, Dorothy Romanus, 267033

TREATMENT OUTCOMES OF PATIENTS WITH MONOCLONAL GAMMOPATHY OF CLINICAL SIGNIFICANCE.

EHA Library, Olga Kudyasheva, 267034

POMALIDOMIDE-BASED TREATMENT IN RELAPSED REFRACTORY MULTIPLE MYELOMA: ANALYSIS OF BASELINE CHARACTERISTICS AND SAFETY PROFILE OF PATIENTS WHO DIED IN THE EUROPEAN POST APPROVAL SAFETY STUDY

EHA Library, Barbara Gamberi, 267035